You are here: Industry Insights > Valsartan

News List

Dr. Reddy's Laboratories Launches Valsartan Tablets, USP in the U.S. Market AmericanPharmaceuticalReview
December 10, 2021
Dr. Reddy’s Laboratories Ltd. announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan® (valsartan) Tablets approved by the U.S. Food and Drug Administration (USFDA).
Sacubitril-Valsartan Does Not Impact Aortic Stiffness in HFrEF drugs
September 05, 2019
For patients with heart failure and reduced ejection fraction (HFrEF), sacubitril-valsartan does not impact aortic stiffness versus enalapril but is associated with improvements in cardiac structure and function...
Valsartan mess to spawn the latest surge of drug injury lawsuits fiercepharma
April 25, 2019
As the FDA and other drug agencies work to limit damage from a massive recall of blood pressure drugs, litigation stemming from the mess is just getting started.
New generic valsartan approved to address shortages europeanpharmaceuticalreview
April 12, 2019
The FDA has prioritised the review of this drug application after multiple recalls of generic valsartan products from several manufacturers…
FDA Approves New Generic Valsartan to Ease Shortage drugs
March 14, 2019
The U.S. Food and Drug Administration on Tuesday approved a new generic version of the high blood pressure/heart failure drug valsartan, saying the move might help ease the current medication shortage.
FDA approves a new generic valsartan worldpharmanews
March 13, 2019
Today, the U.S. Food and Drug Administration approved a new generic of Diovan (valsartan).
A third cancer-causing impurity detected in U.S. supply of blood pressure drug fiercepharma
March 08, 2019
Just when it appeared the FDA was close to purging the U.S. drug supply of potential cancer-causing impurities in sartan blood pressure drugs, another massive recall has been launched. This time it is for an entirely new contaminant.
Pfizer recalls valsartan-containing blood pressure drug in Japan pharmaceutical-technology
February 13, 2019
Pfizer’s subsidiary in Japan has announced a recall of blood pressure drug Amvalo that was found to contain impurities in its active ingredient valsartan, which is indicated to treat high blood pressure....
FDA moving to 'risk-based' inspections even as valsartan scare adds new wrinkle to oversight fiercepharma
January 31, 2019
FDA inspections of generic drug plants are on the rise and should continue to increase through 2019, Commissioner Scott Gottlieb said this week in a series of tweets.
FDA’s aggressive move on tainted ‘sartan’ leads to shortages fiercepharma
January 29, 2019
The FDA took aggressive action when it learned that some “sartan” drugs contained a probable carcinogen which developed during manufacturing.

Previous page 1 2 3 Next page